Filing Flows › Glaukos (GKOS) › Q3 2026 › vs Q2 2026
Glaukos (GKOS) Q3 2026 vs Q2 2026 (quarter over quarter)
Glaukos's revenue rose $25.4M (+14%) from $186M in Q2 2026 to $211M in Q3 2026. The biggest changes: Corneal Health +$28.6M (+94%); Glaucoma −$3.2M (-2%). Gross margin 85.2% against 81.7% (+3.6 pts).
Glaukos, Q3 2026: revenue $211M (+58% year over year), operating margin 0.4%, net earnings $2.0M, operating cash flow $38.6M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 85.2% | 81.7% | +3.6 pts |
| Operating margin | 0.4% | -9.3% | +9.7 pts |
| Net margin | 1.0% | -9.9% | +10.9 pts |
| Free cash flow margin | 17.3% | 6.5% | +10.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Glaucoma | $152M | $155M | −$3.2M | -2% |
| Corneal Health | $59.0M | $30.4M | $28.6M | +94% |
| Revenue | $211M | $186M | $25.4M | +14% |
| Gross profit | $180M | $152M | $28.3M | +19% |
| Cost of revenue | $31.2M | $34.0M | −$2.9M | -8% |
| Other income, net | $1.5M | −$454K | $1.9M | — |
| Operating profit | $828K | −$17.3M | $18.1M | — |
| Operating expenses | $179M | $169M | $10.2M | +6% |
| Pre-tax earnings | $2.3M | −$17.7M | $20.0M | — |
| Research & development | $31.0M | $51.3M | −$20.3M | -40% |
| Other operating costs | $17.1M | $1.5M | $15.6M | 11× |
| Net earnings | $2.0M | −$18.4M | $20.4M | — |
| Income tax | $303K | $656K | −$353K | -54% |
| Depreciation & amortization | $9.0M | $8.9M | $83K | +0.9% |
| Share-based compensation | $17.8M | $28.9M | −$11.1M | -38% |
| Working capital & other | $9.8M | −$4.5M | $14.4M | — |
| Operating cash flow | $38.6M | $14.8M | $23.7M | +160% |
| Free cash flow (OCF − capex) | $36.5M | $12.1M | $24.4M | +202% |
| Capital expenditures | $2.1M | $2.7M | −$659K | -24% |
Questions
How much did Glaukos's revenue grow quarter over quarter in Q3 2026?
Glaukos's revenue rose $25.4M (+14%) from $186M in Q2 2026 to $211M in Q3 2026.
What drove Glaukos's revenue change in Q3 2026?
Corneal Health +$28.6M (+94%); Glaucoma −$3.2M (-2%).